KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Research Development Expenses

Last Annual Value

30.75M

3-Year CAGR

38%

5-Year CAGR

-9%

10-Year CAGR

-5%

KT

Kalaris Therapeutics Inc Competitors Analysis of research-development-expenses

KLRS · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
30.75M
38.0%-23.8%N/A 
25.58M
-3.6%-11.4%10.3%
69.54M
11.4%10.4%N/A
35.27M
-22.0%-9.0%N/A
31.86M
21.5%53.0%N/A
94.43M
0.0%45.5%N/A
77.04M
-0.2%-2.9%9.3%
77.00M
-18.4%5.1%N/A
74.54M
25.1%23.0%N/A
19.52M
-26.6%-8.7%N/A
6.38M
-10.7%-21.2%-1.9%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66